Feasibility of Predicted Heart Mass in Patients with Single Ventricle Physiology

Isabel Eng, Jeannette Lin MD, Weiyi Tan MD, Leigh Reardon MD, Gentian Lluri MD, PhD Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA

David Geffen School of Medicine

INTRODUCTION

• The Fontan procedure is a palliative surgical procedure employed in patients with single ventricle congenital defects.¹




Figure 1. Fontan procedure for tricuspid atresia⁶

- Fontan patients may require orthotopic heart transplant (OHT) or combined heart-liver transplant (CHLT) as a final therapeutic option.¹
- Single ventricle patients have been shown to have 3x higher risk of in-hospital mortality post OHT vs patients with biventricular physiology.5
- Predicted heart mass (PHM) has been found to be the optimal size match metric in predicting mortality post heart transplant.³
- Undersizing donor hearts (PHM ratio < 0.83) is associated with increased mortality³; however, questions remain regarding how to properly size donor organs in Fontan patients. At UCLA, we currently consider donor to recipient height ratios, weight ratios, age; cross-sectional imaging to directly measure donor and recipient cardiac and liver dimensions.
- In adults with Fontan physiology, we sought to understand:
 - The utility of PHM in sizing donor organs for OHT/CHLT
 - Optimal donor heart sizing for OHT vs CHLT
 - Factors predicting improved survival vs morbidity

METHODS

- Retrospectively, 30 adult patients with failing Fontan physiology who underwent OHT/CHLT at UCLA from 2010-2020 were identified for a descriptive analysis of clinical data.
- Data collected included patient history, donor/recipient organ listing details, and transplant details.
- PHM and PHM ratios were calculated using the Calculate by QxMD Calculator⁷ and the UNOS PHM Match Calculator.⁸

RESULTS

Table 1. Combined Heart/Liver Transplants at UCLA, 2010-2020

| Congenital Heart Diagnosis | Heterotaxy (Y/N) | Age at Transplant (years) | Recipient PHM (g) | Donor PHM (g) | Donor: Recipient PHM | Outcome |
|----------------------------------|---------------------|---------------------------------|-------------------------|---------------------|----------------------------|----------------------------|
| L-TGA, TA | N | 33.93 | 162.93 | 167.82 | 1.03 | Alive 10 mo post-txp |
| TA | N | 32.25 | 185.61 | 206.03 | 1.11 | Alive 10 mo post-txp |
| DORV, L- | N | 23.91 | 96.93 | 125.04 | 1.29 | Alive 1.5 yrs post-txp |
| TGA | | | | | | |
| TA | N | 40.37 | 139.44 | 138.46 | 0.993 | Alive 2 yrs, 4 mo post-txp |
| DILV | N | 53.28 | 180.11 | 181.70 | 1.01 | Alive 2 yrs, 7 mo post-txp |
| CAVC | N | 43.20 | 140.85 | 180.29 | 1.28 | Expired 4 days post-txp |
| | | | | | | (anoxic brain injury) |
| TA | N | 39.54 | 116.17 | 153.34 | 1.32 | Alive 4 yrs, 3 mo post-txp |
| TA | N | 40.11 | 181.12 | 195.61 | 1.08 | Alive 4 yrs, 9 mo post-txp |
| HLHS | N | 20.67 | 170.74 | 177.57 | 1.04 | Alive 7 yrs, 6 mo post-txp |
| DORV, | N | 30.44 | 122.67 | 152.11 | 1.24 | Alive 9 yrs, 2 mo post-txp |
| VSD | | | | | | |

L-TGA = left transposition of great arteries, TA= tricuspid atresia, DORV = double outlet right ventricle, DILV = double inlet left ventricle, CAVC= complete atrioventricular canal defect, HLHS = hypoplastic left heart syndrome, VSD = ventricular septal defect, Txp=transplant

Table 2. Orthotopic Heart Transplants at UCLA, 2010-2020

| Congenital Heart Diagnosis | Heterotaxy (Y/N) | Age at Transplant (years) | Recipient PHM (g) | Donor PHM (g) | Donor: Recipient PHM | Outcome |
|----------------------------------|---------------------|---------------------------------|-------------------------|---------------------|----------------------------|--|
| DILV, L- TGA | N | 36.68 | 129.55 | 185.26 | 1.43 | Alive 10 mo post-txp |
| Unbalanced AV Canal | Y | 40.05 | 192.85 | 202.49 | 1.05 | Alive 1 yr, 1 mo post-txp |
| Unbalanced AV Canal | Y | 18.78 | 196.42 | 157.14 | 0.80 | Alive 1 yr, 6 mo post-txp |
| TA | N | 22.33 | 95.22 | 113.31 | 1.19 | Alive 5 yrs, 3 mo post-txp |
| Unbalanced AV Canal | N | 20.35 | 150.54 | 173.12 | 1.15 | Expired 2 yrs, 21 days post-txp (sudden death) |
| L-TGA, TA | N | 43.54 | 164.93 | 174.83 | 1.06 | Alive 7 yrs, 8 mo post-txp |
| Unbalanced AV Canal | Y | 25.47 | 116.24 | 168.55 | 1.45 | Alive 7 yrs, 10 mo post-txp |
| DORV, Mitral Atresia | Y | 22.45 | 111.02 | 115.46 | 1.04 | Alive 8 yrs, 1 mo post-txp |
| TA | N | 45.85 | 184.04 | 176.68 | 0.96 | Alive 8 yrs, 9 mo post-txp |
| TA | N | 43.50 | 120.94 | 150.42 | 1.31 | Alive 10 yrs, 1 mo post-txp |
| D-TGA, VSD, | N | 33.75 | 116.44 | 131.58 | 1.13 | Alive 10 yrs, 5 mo post-txp |
| Pulmonary Atresia | | | | | | |
| DILV | N | 32.84 | 154.62 | 180.91 | 1.17 | Alive 11 yrs, 2 mo post-txp |
| TA | N | 35.15 | 114.10 | 123.23 | 1.08 | Alive 11 yrs, 4 mo post-txp |

L-TGA = left transposition of great arteries, TA= tricuspid atresia, DORV = double outlet right ventricle, DILV = double inlet left ventricle, CAVC= complete atrioventricular canal defect, HLHS = hypoplastic left heart syndrome, VSD = ventricular septal defect, Txp=transplant

Table 3. Comparison of PHM ratios for CHLT vs OHT

| Transplant Type | Donor: Recipient PHM Ratio | | |
|--------------------------------------|----------------------------|--|--|
| Combined Heart/Liver (mean, std dev) | 1.14±0.13 | | |
| Orthotopic Heart (mean, std dev) | 1.14±0.18 | | |

CONCLUSION

- When using our current selection factors, the donor to recipient PHM ratio would be considered "moderately oversized."
- Despite concern for oversized donor livers, mean donor to recipient PHM ratios in our patient population were comparable for OHT vs CHLT.
- Limitations of this study:
 - Though UCLA performs a high volume of Fontan OHT/CHLTs, the patient population remains small, thus making it difficult to draw conclusions about factors impacting survival.
 - Differences in surgeons, technique, and approach to risk modification are important confounders.

FUTURE DIRECTIONS

- Multicenter study pooling experience for additional insight into donor size selection.
 - May again prove difficult to draw conclusions about outcomes given highly variable practice patterns.
- Further investigation of factors predicting survival and morbidity are warranted for this specialized patient population.

REFERENCES

- 1. Heart and heart-liver transplantation in adults with failing Fontan physiology: Reardon LC, DePasquale EC, Tarabay J, et al. Heart and heart-liver transplantation in adults with failing Fontan physiology. Clin Transplant. 2018;32:e13329. https://doi.org/10.1111/ctr.13329
- 2. Deal BJ, Jacobs ML. Management of the failing Fontan circulation. Heart. 2012 Jul;98(14):1098-104. doi: 10.1136/heartjnl-2011-301133. PMID: 22739639; PMCID: PMC3386650.
- 3. Kransdorf EP, Kittleson MM, Benck LR, Patel JK, Chung JS, Esmailian F, Kearney BL, Chang DH, Ramzy D, Czer LSC, Kobashigawa JA. Predicted heart mass is the optimal metric for size match in heart transplantation. J Heart Lung Transplant. 2019 Feb;38(2):156-165. doi: 10.1016/j.healun.2018.09.017. Epub 2018 Sep 27. PMID: 30528987.
- 4. Clark DE, Byrne RD, Mazurek JA, Opotowsky AR, Schlendorf KH, Xu M, Zalawadiya S, Menachem JN. Sizing heart transplant donors in adults with congenital heart disease. J Thorac Cardiovasc Surg. 2020 Feb 28:S0022-5223(20)30508-0. doi: 10.1016/j.jtcvs.2020.01.099. Epub ahead of print. PMID: 32222406.
- 5. Kenny LA, DeRita F, Nassar M, Dark J, Coats L, Hasan A. Transplantation in the single ventricle population. Ann Cardiothorac Surg. 2018;7(1):152-159. doi:10.21037/acs.2018.01.16
- 6. https://en.wikipedia.org/wiki/Fontan_procedure
- 7. https://qxmd.com/calculate/calculator_654/predicted-heart-mass-calculator-phm
- 8. https://insights.unos.org/phm-calculator/